Literature DB >> 33994729

Molecular Oncology of Gall Bladder Cancer.

Arun Chaturvedi1, Vijay Kumar1, Sameer Gupta1.   

Abstract

Gall bladder carcinoma (GBC) is a worldwide problem, with a higher incidence in areas of the world where cholelithiasis is common. As GBC is usually diagnosed in an advanced stage, the mortality is high. An understanding of the molecular pathways of carcinogenesis and the mutations involved in the development and progression of GBC could be useful in early diagnosis. Understanding molecular markers of prognosis as well as predictors of outcome could also potentially benefit patients undergoing treatment. New therapies targeting major molecular pathways and immunotherapy are exciting novel therapeutic options. This review focuses on the current understanding of the molecular oncology of GBC. © Indian Association of Surgical Oncology 2019.

Entities:  

Keywords:  Biliary cancers; Gall bladder carcinoma; Immunotherapy; Molecular oncology; Mutations; Targeted therapy

Year:  2019        PMID: 33994729      PMCID: PMC8119519          DOI: 10.1007/s13193-019-01008-2

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  54 in total

Review 1.  Preneoplastic lesions in gallbladder cancer.

Authors:  Iván Roa; Xabier de Aretxabala; Juan C Araya; Juan Roa
Journal:  J Surg Oncol       Date:  2006-06-15       Impact factor: 3.454

2.  N-cadherin and P-cadherin are biomarkers for invasion, metastasis, and poor prognosis of gallbladder carcinomas.

Authors:  Shengen Yi; Zhu-Lin Yang; Xiongying Miao; Qiong Zou; Jinghe Li; Lufeng Liang; Guixiang Zeng; Senlin Chen
Journal:  Pathol Res Pract       Date:  2014-02-22       Impact factor: 3.250

Review 3.  Genetics of biliary tract cancers and emerging targeted therapies.

Authors:  Aram F Hezel; Vikram Deshpande; Andrew X Zhu
Journal:  J Clin Oncol       Date:  2010-06-14       Impact factor: 44.544

4.  Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.

Authors:  Kumiko Nakazawa; Yoh Dobashi; Shioto Suzuki; Hideki Fujii; Yasuhisa Takeda; Akishi Ooi
Journal:  J Pathol       Date:  2005-07       Impact factor: 7.996

5.  Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.

Authors:  Yasuo Koga; Yoshihiko Kitajima; Atsushi Miyoshi; Ken Sato; Kenji Kitahara; Hidenobu Soejima; Kohji Miyazaki
Journal:  Ann Surg Oncol       Date:  2005-03-31       Impact factor: 5.344

Review 6.  Gallbladder cancer: lessons from a rare tumour.

Authors:  Ignacio I Wistuba; Adi F Gazdar
Journal:  Nat Rev Cancer       Date:  2004-09       Impact factor: 60.716

7.  Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer.

Authors:  Masanori Kobayashi; Tomoyo Sakabe; Hirofumi Abe; Mitsugu Tanii; Hidenori Takahashi; Asako Chiba; Eri Yanagida; Yuta Shibamoto; Masahiro Ogasawara; Shun-ichi Tsujitani; Shigeo Koido; Kazuhiro Nagai; Shigetaka Shimodaira; Masato Okamoto; Yoshikazu Yonemitsu; Noboru Suzuki; Masaki Nagaya
Journal:  J Gastrointest Surg       Date:  2013-07-20       Impact factor: 3.452

Review 8.  Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience.

Authors:  De-Qing Mu; You-Shu Peng; Qiao-Jian Xu
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

9.  Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Authors:  Juan W Valle; Harpreet Wasan; Andre Lopes; Alison C Backen; Daniel H Palmer; Karen Morris; Marian Duggan; David Cunningham; D Alan Anthoney; Pippa Corrie; Srinivasan Madhusudan; Anthony Maraveyas; Paul J Ross; Justin S Waters; Will P Steward; Charlotte Rees; Sandy Beare; Caroline Dive; John A Bridgewater
Journal:  Lancet Oncol       Date:  2015-07-12       Impact factor: 41.316

10.  Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.

Authors:  Masafumi Ikeda; Tatsuya Ioka; Akira Fukutomi; Chigusa Morizane; Akiyoshi Kasuga; Hideaki Takahashi; Akiko Todaka; Takuji Okusaka; Caretha L Creasy; Shelby Gorman; Daniel J Felitsky; Mikiro Kobayashi; Fanghong Zhang; Junji Furuse
Journal:  Cancer Sci       Date:  2017-12-09       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.